Recruiting

Observational Study

Sponsor:

Ottawa Hospital Research Institute

Code:

NCT02185365

Conditions

Developmental Dysplasia of the Hip

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Magnetic Resonance Imaging (MRI)

Study Details

Brief summary:

One of the leading causes of hip arthritis is developmental dysplasia of the hip (DDH). DDH can lead to major damage in the hip joint and may result in hip arthritis later in life. Patients recruited into this study will be undergoing corrective hip surgery within the next 6 months with a goal of preventing further hip problems down the road. This study is being done to see how well a newer type of Magnetic Resonance Imaging (MRI) detects hip cartilage damage compared to an older but well validated MRI method.

Conditions

Developmental Dysplasia of the Hip

Study ID

NCT02185365

Start date

Jul 25, 2017

Status verified date

Jun, 2021

Completion date

Dec, 2021

Anticipated

Primary completion date

Dec, 2021

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • patients with a diagnosis of developmental dysplasia of the hip (DDH)

Exclusion Criteria:

  • patients under the age of 18
  • pregnancy and/or lactation
  • non-MRI compatible implants (stents, electronic devices, cardiac pacers or wires)
  • severe claustrophobia
  • prior contrast allergic reaction
  • kidney impairment
  • previous hip surgery
  • osteoarthritis on conventional radiographs (Tönnis Grade>0)
  • additional underlying hip diseases such as posttraumatic arthritis, Legg-Calvé-Perthes-Disease (LCPD), or slipped capital femoral epiphysis (SCFE)

Study Design

Enrollment

25 participants

Anticipated

Interventions and Outcome Measures

Arms

Developmental dysplasia of the hip (DDH)

Patients will complete 2 magnetic resonance imaging (MRI): T1-rho and dGEMRIC. The T1-rho MRI does not require the injection of a contrast agent, while the dGEMRIC MRI requires a gadolinium injection to visualize cartilage in the hip.

Interventions

Magnetic Resonance Imaging (MRI)

Patients will undergo 2 different MRIs of the affected hip. Both MRIs assess hip cartilage degeneration. A contrast agent, Gadolinium, will be used to visualize cartilage during the MRI. The contrast agent is injected through an intravenous (a small plastic tube inserted into a vein in the patients' arm) before the MRI.

Primary outcome measure

  • Assess proteoglycan amounts in hip cartilage [ Time Frame: Within the 6 months prior to surgery ]

Central Contacts and Locations

Central contacts

Paul Beaule, MD, FRCSC

613-737-8899pbeaule@toh.ca

Cheryl Kreviazuk

613-737-8920ckreviazuk@ohri.ca

Locations

Ottawa Hospital - General Campus

Recruiting

Ottawa, Ontario, Canada, K1H8L6

Contacts

Orthopaedic Research

613-737-8920

Principal Investigator:

Paul Beaule, MD

More Information

Sponsor

Ottawa Hospital Research Institute

Last update posted

Jun 23, 2021

Last verified

Jun, 2021

Keywords

  • T1-rho MRI
  • dGEMRIC MRI
  • DDH
  • Developmental dysplasia of the hip

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Ottawa Hospital Research Institute on 2021-06-23.